Batanopride

Batanopride (BMY-25,801) is an antiemetic drug of the benzamide class which acts as a selective 5-HT3 receptor antagonist.[1] It was trialled to reduce nausea during cancer chemotherapy, but was never approved for medical use due to dose-limiting side effects including hypotension and long QT syndrome.[2]

Batanopride
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC17H26ClN3O3
Molar mass355.86 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

References

  1. Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR (March 1988). "BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties". The Journal of Pharmacology and Experimental Therapeutics. 244 (3): 830–7. PMID 2978041.
  2. Fleming GF, Vokes EE, McEvilly JM, Janisch L, Francher D, Smaldone L. "Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis". Cancer Chemotherapy and Pharmacology. 28 (3): 226–7. doi:10.1007/bf00685516. PMID 1855280.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.